Links

Some of the sources I used. I'll try to integrate them into the DD in order later on.

https://seer.cancer.gov/statfacts/html/breast-subtypes.html

https://www.nof.org/news/new-report-on-burden-of-osteoporosis-highlights-huge-and-growing-economic-and-human-toll-of-the-disease/

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01129-0/fulltext

https://ascopost.com/issues/february-10-2016/tamoxifen-or-anastrozole-for-ductal-carcinoma-in-situ-choice-comes-down-to-side-effects-and-patient-preference/

https://www.breastcancer.org/research-news/20101003

https://www.hematologyandoncology.net/archives/february-2018/the-development-of-endoxifen-for-breast-cancer/

https://www.gilead.com/news-and-press/press-room/press-releases/2020/9/gilead-sciences-to-acquire-immunomedics

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2740485/

https://www.hindawi.com/journals/ijso/2015/785793/

https://www.tandfonline.com/doi/full/10.1080/17512433.2019.1610390#:~:text=Introduction%3A%20Tamoxifen%20dominates%20the%20anti,times%20more%20potent%20metabolite%2C%20endoxifen.

https://academic.oup.com/endo/article/158/10/3354/4060084

https://education.questdiagnostics.com/faq/FAQ146

https://www.cancer.gov/news-events/cancer-currents-blog/2017/endoxifen-breast-cancer-nci-support

https://pharmaacumen.com/journal/2017/3/1/using-reformulation-as-a-strategy-four-critical-factors-for-success